Skip to main content
. Author manuscript; available in PMC: 2020 Dec 9.
Published in final edited form as: Ophthalmol Retina. 2019 Nov 11;4(12):1138–1145. doi: 10.1016/j.oret.2019.11.004

Table 3.

Distribution of nvAMD OCT lesion characteristics at weekly time points from baseline until week 4 post-injection with Ranibizumab.

OCT lesion characteristics (n=48) Baseline Week 1 Week 2 Week 3 Week 4
Retinal Cysts 32 (66.67%) 15 (31.25%) 10 (20.83%) 12 (25%) 16 (33.33%)
Subretinal Fluid 26 (54.17%) 16 (33.3%) 13 (27.08%) 11 (22.92%) 16 (33.33%)
Pigment Epithelial Detachment 27 (56.25%) 18 (37.5%) 13 (27.08%) 12 (25%) 13 (27.08%)